secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2026-02-05T23:59:59+00:00
Accession:  0001104659-26-010668
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode submits IND amendment for Phase 2a trial of TTX-MC138 in colorectal cancer
--------------------------------------------------------------------------------

- IND amendment filed with FDA for Phase 2a dose-expansion trial of TTX-MC138 in colorectal cancer patients with ctDNA-positive MRD.
- Trial to enroll up to 45 patients who completed curative-intent therapy; expected start in first half 2026.
- Study conducted by Quantum Leap Healthcare within PRE-I-SPY platform, its first expansion into colorectal cancer.
- Principal Investigator Dr. Paula Pohlmann of MD Anderson Cancer Center leads the trial.
- Collaboration with Quantum Leap and support from Colorectal Cancer Alliance; trial ID NCT05868226.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465926010668/0001104659-26-010668-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465926010668/tm265309d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-010668

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer